Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T33451 |
ML 7
ML7,ML-7 |
||
ML 7 is an inhibitor of myosin light chain kinase that protects cardiac function from ischemia/reperfusion (I/R) injury. | |||
T3050 |
ML-7 hydrochloride
ML-7 HCl,ML-7盐酸盐 |
Serine/threonin kinase; Myosin; YAP; PKA; PKC | Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; Metabolism; Stem Cells; Tyrosine Kinase/Adaptors |
ML-7 hydrochloride (ML-7 HCl) 是一种可渗透细胞的、可逆的、有效的、ATP 竞争性的肌球蛋白轻链激酶(MLCK) 特异性抑制剂,IC50为300 nM。它还抑制平滑肌肌球蛋白轻链激酶、PKA 和 PKC。 | |||
T11185 |
EML741
|
Histone Methyltransferase | Chromatin/Epigenetic |
EML741 also inhibits DNMT1 (IC50, 3.1 μM), with no effect on DNMT3a or DNMT3b. EML741 exhibits low cell toxicity, and is membrane permeable and blood-brain barrier penetrated. EML741 is a histone lysine methyltransferase G9a/GLP inhibitor, with an IC50 of 23 nM, Kd of 1.13 μM for G9a. | |||
T16113 | ML753286 | AMPK | Chromatin/Epigenetic; PI3K/Akt/mTOR signaling |
ML753286 has high permeability and low to medium clearance in rodent and human liver S9 fractions. ML753286 is an orally active and selective inhibitor of BCRP (IC50: 0.6 μM). It is also stable in plasma across species. | |||
T79614 |
EML734
|
Histone Methyltransferase | Chromatin/Epigenetic |
EML734为PRMT7/9的选择性抑制剂,其对PRMT7的IC50为315 nM,对PRMT9的IC50为0.89 μM。 | |||
T72861 | (6R)-ML753286 | ||
(6R)-ML753286 是 ML753286 的异构体。ML753286 是一种口服活性和选择性 BCRP(抗乳腺癌蛋白) 抑制剂,IC50为 0.6 μM。 ML753286 在啮齿动物和人类肝脏 S9 组分中具有高渗透性和低至中等清除率,并且在不同物种中都具有血浆稳定性。 | |||
T10490 |
(S)-ML753286
|
Others | Others |
(S)-ML753286 is a breast cancer resistance protein (BCRP) inhibitor (IC50: 0.6 μM on BCRP efflux transporter). |